It is transiently overexpressed following T cell activation but can also be robustly and durably overexpressed in cancer cells which exploit this mechanism to inhibit immune responses, notably the anti-tumor cytolytic activities of CD8+ T cells and/or natural killer cells [30,31]. This evidence concerns the gene CD8A and cancer.